The Ministry of Health and Community Protection issued instructions to all health facilities and all doctors informing them of the cautious suspension of the registration of all products containing ranitidine with a suspension of its import and distribution, provided that the withdrawal is not made until confirmed. the NDMA ratio from international authorities. Based on recommendations from the US Food and Drug Administration, the European Medicines Administration and the Canadian Health Authority regarding the contamination of products containing ranitidine with NDMA impurity (N-nitrosodimethylamine) classified as human carcinogens based on the results of laboratory tests.
The circular, signed by Dr Amin Hussein Al-Amiri, Assistant Undersecretary for Public Health Policy and Licenses, head of the Supreme Committee for Pharmacovigilance, said the ministry does not recommend patients stop taking ranitidine, which is used for treatment and ulcers in the stomach and intestines, as well as cases where the stomach produces too much acid.
The Circle urges patients who wish to stop using the product for potential contamination to consult a healthcare professional to replace the product with another medicine, in line with recommendations from global drug authorities. Many of these products are registered with the Department of Medicine at the Ministry of Health and Community Protection.
Dr Rukaya Al Bastaki, director of the Department of Medicines Administration at the ministry, said the circle came after reviewing procedures followed by international health authorities such as the US Food and Drug Administration, the European Medicines Administration and the Canadian Health Authority and urged them to patients to communicate with the Ministry in the event of any adverse effects caused by the Use of the above products by telephone: 04 04 2301448 or e-mail: firstname.lastname@example.org, notification via the Minister's website or through the UAERADR application.
The Department of Health and Community Care is ready to maintain contact with local and international pharmaceutical plants, the US Food and Drug Administration and the European Medicines Administration. By taking preventive measures and monitoring the implementation of circular services with agents to ensure implementation, within its strategy of building quality systems and therapeutic safety, health and pharmaceuticals to international standards.